Clinical Trial Update: AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) [Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 2 study of AB-16B5 in combination with docetaxel for metastatic non-small cell lung cancer; the trial st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AB-16B5
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Alethia Biotherapeutics | Conditions: NSCLC Stage IV | Phase 2 | Status: COMPLETED | Results posted: 2025-04-06